Patents by Inventor Joe McCann

Joe McCann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RADIOPHARMACEUTICAL AND METHODS
    Publication number: 20240108765
    Abstract: The radiopharmaceutical 177Lu-PSMA I&T is provided, including in high purities with extended shelf life. Further provided are methods of synthesis of 177Lu-PSMA I&T and pharmaceutical compositions and methods of treatment that comprise 177Lu-PSMA I&T.
    Type: Application
    Filed: April 17, 2023
    Publication date: April 4, 2024
    Inventor: Joe McCann
  • RADIOPHARMACEUTICAL AND METHODS
    Publication number: 20230302163
    Abstract: The radiopharmaceutical 177Lu-PSMA I&T is provided, including in high purities with extended shelf life. Further provided are methods of synthesis of 177Lu-PSMA I&T and pharmaceutical compositions and methods of treatment that comprise 177Lu-PSMA I&T.
    Type: Application
    Filed: September 22, 2022
    Publication date: September 28, 2023
    Inventor: Joe McCann
  • RADIOPHARMACEUTICAL AND METHODS
    Publication number: 20220387637
    Abstract: A radiopharmaceutical 177Lu-DOTATATE compound, a composition, and a kit are provided. Further provided are methods of synthesis of a 177Lu-DOTATATE compound and methods of treatment that comprise a 177Lu-DOTATATE compound.
    Type: Application
    Filed: August 4, 2022
    Publication date: December 8, 2022
    Inventors: Joe McCann, Justyna Kelly, Paul Billone
  • Radiopharmaceutical and methods
    Patent number: 11491246
    Abstract: The radiopharmaceutical 177Lu-PSMA I&T is provided, including in high purities with extended shelf life. Further provided are methods of synthesis of 177Lu-PSMA I&T and pharmaceutical compositions and methods of treatment that comprise 177Lu-PSMA I&T.
    Type: Grant
    Filed: July 13, 2021
    Date of Patent: November 8, 2022
    Assignee: POINT Biopharma, Inc.
    Inventor: Joe McCann
  • Radiopharmaceutical and methods
    Patent number: 11439714
    Abstract: A radiopharmaceutical 177Lu-DOTATATE compound, a composition, and a kit are provided. Further provided are methods of synthesis of a 177Lu-DOTATATE compound and methods of treatment that comprise a 177Lu-DOTATATE compound.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: September 13, 2022
    Assignee: Centre for Probe Development and Commercialization
    Inventors: Joe McCann, Justyna Kelly, Paul Billone
  • RADIOPHARMACEUTICAL AND METHODS
    Publication number: 20220062447
    Abstract: A radiopharmaceutical 177Lu-DOTATATE compound, a composition, and a kit are provided. Further provided are methods of synthesis of a 177Lu-DOTATATE compound and methods of treatment that comprise a 177Lu-DOTATATE compound.
    Type: Application
    Filed: August 30, 2021
    Publication date: March 3, 2022
    Inventors: Joe McCann, Justyna Kelly, Paul Billone
  • RADIOPHARMACEUTICAL AND METHODS
    Publication number: 20220016274
    Abstract: The radiopharmaceutical 177Lu-PSMA I&T is provided, including in high purities with extended shelf life. Further provided are methods of synthesis of 177Lu-PSMA I&T and pharmaceutical compositions and methods of treatment that comprise 177Lu-PSMA I&T.
    Type: Application
    Filed: September 27, 2021
    Publication date: January 20, 2022
    Inventor: Joe McCann
  • RADIOPHARMACEUTICAL AND METHODS
    Publication number: 20220008564
    Abstract: The radiopharmaceutical 177Lu-PSMA I&T is provided, including in high purities with extended shelf life. Further provided are methods of synthesis of 177Lu-PSMA I&T and pharmaceutical compositions and methods of treatment that comprise 177Lu-PSMA I&T.
    Type: Application
    Filed: July 13, 2021
    Publication date: January 13, 2022
    Inventor: Joe McCann
  • Radiopharmaceutical and methods
    Patent number: 11129912
    Abstract: The radiopharmaceutical 177Lu-PSMA I&T is provided, including in high purities with extended shelf life. Further provided are methods of synthesis of 177Lu-PSMA I&T and pharmaceutical compositions and methods of treatment that comprise 177Lu-PSMA I&T.
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: September 28, 2021
    Assignee: POINT Biopharma Inc.
    Inventor: Joe McCann